Fevipiprant, a selective prostaglandin D2 receptor 2 antagonist, inhibits human group 2 innate lymphoid cell aggregation and function
Main Authors: | , , , , , , , , , , , |
---|---|
Format: | Journal article |
Published: |
Elsevier
2019
|
Summary: |
---|